Dianthus Therapeutics (DNTH) Cash from Financing Activities (2017 - 2025)

Dianthus Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $274.5 million for Q3 2025.

• In Q3 2025, Cash from Financing Activities rose 92640.88% year-over-year to $274.5 million; the TTM figure through Sep 2025 stood at $314.9 million (up 49.19% YoY), while the FY2024 annual figure was $255.6 million, up 91.37% from the prior year.
• Cash from Financing Activities for Q3 2025 stood at $274.5 million, up from $568000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $274.5 million in Q3 2025, with the low at -$4.9 million in Q4 2023.
• The 5-year median for Cash from Financing Activities is $418000.0 (2021), against an average of $56.7 million.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities tumbled 99.94% in 2022, then jumped 92640.88% in 2025.
• Dianthus Therapeutics' Cash from Financing Activities stood at $124000.0 in 2021, then soared by 77825.0% to $96.6 million in 2022, then slumped by 105.03% to -$4.9 million in 2023, then surged by 915.54% to $39.7 million in 2024, then soared by 591.89% to $274.5 million in 2025.
• Business Quant data shows DNTH's Cash from Financing Activities at $274.5 million in Q3 2025, $568000.0 in Q2 2025, and $161000.0 in Q1 2025.